Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

(2009) J.-L. Harousseau et al.   BLOOD

Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial

(2009) Delphine Rolland et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer

(2009) J. A. Sparano et al.   CLINICAL CANCER RESEARCH

Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis

(2009) Haiming Dai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

βTrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis

(2009) Elinor Dehan et al.   MOLECULAR CELL

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

(2008) J. E. Karp et al.   BLOOD

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

(2008) K. J. Mavrakis et al.   GENES & DEVELOPMENT

Multisite Phosphorylation Regulates Bim Stability and Apoptotic Activity

(2008) Anette Hübner et al.   MOLECULAR CELL

Apoptosis: controlled demolition at the cellular level

(2007) Rebecca C. Taylor et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY